Filipino Filipino
en Englishaf Afrikaanssq Albanianar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbg Bulgarianca Catalanzh-CN Chinese (Simplified)zh-TW Chinese (Traditional)hr Croatiancs Czechda Danishnl Dutchet Estoniantl Filipinofi Finnishfr Frenchgl Galicianka Georgiande Germanel Greekht Haitian Creoleiw Hebrewhi Hindihu Hungarianis Icelandicid Indonesianga Irishit Italianja Japaneseko Koreanlv Latvianlt Lithuanianmk Macedonianms Malaymt Malteseno Norwegianfa Persianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsw Swahilisv Swedishth Thaitr Turkishuk Ukrainianur Urduvi Vietnamesecy Welshyi Yiddish

Pinakabagong Balita

Inanunsyo ng BioMarin ang Matibay na Hemostatic Efficacy na Napanatili Higit sa 6 na taon sa Patuloy na Phase 1/2 na Pag-aaral ng Valoctocogene Roxaparvovec, Investigational Gene Therapy para sa Hemophilia A

Inanunsyo ng BioMarin ang Matibay na Hemostatic Efficacy na Napanatili Higit sa 6 na taon sa Patuloy na Phase 1/2 na Pag-aaral ng Valoctocogene Roxaparvovec, Investigational Gene Therapy para sa Hemophilia A
Super Gumagamit
Super Gumagamit
Back To Top
Imahen

Please enable the javascript to submit this form

tungkol sa

Sinusuportahan ng mga grant na pang-edukasyon mula sa Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, at uniQure, Inc.

Mahalagang SSL